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CASE PRESENTATION
A 3-month-old term nonconsanguineous female infant was found
to have a bulging anterior fontanelle at her 2-month visit. Two
weeks later upon presenting to the emergency room with a viral
illness, investigations showed hypophosphatemia 0.49 mmol/L
(1.3 to 2.6 mmol/L), normocalcemia 2.65 mmol/L (2.24 to
2.74 mmol/L), and parathyroid hormone (PTH) <0.3 pmol/L
(1.6 to 6.9 pmol/L). Workup for hypophosphatemia including
head and renal ultrasounds was unremarkable. X-rays showed
flaring of metaphyses in femurs, tibiae, and fibulae, and she was
started on phosphate (3 mmol 4 times a day) and vitamin D
(Calcitriol equivalent to 1,000 IU daily) for presumed congenital rickets. Two weeks into treatment, she was admitted to the
Paediatric Critical Care Unit with status epilepticus secondary to
hypocalcemia with an ionized calcium of 0.97 mmol/L (1.09 to
1.3 mmol/L). 1,25-Dihydroxy Vitamin D levels returned at >480
pmol/L (60 to 208 pmol/L) ruling out congenital rickets. She
had significant anemia with hemoglobin 85 g/L (100 to 140 g/L),
thrombocytopenia 131×10^9/L (150 to 400×10^9/L), and
blasts (0.141×10^9/L) on peripheral smears. Clinical examination revealed nystagmus and no hepatosplenomegaly. Skeletal
survey showed a new finding of diffuse bone sclerosis along with
fraying of metaphyses diffusely (Figures 1 and 2). A head magnetic resonance imaging demonstrated enlarged lateral and third
ventricles (Figure 3). A bone marrow biopsy sample was difficult
to obtain. However, findings of hypophosphatemia, hypocalcemia, bicytopenia, and x-ray abnormalities prompted molecular
studies, which confirmed the diagnosis.

Figure 1. Extensive sclerosis of femurs and fraying of metaphyses
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DIAGNOSIS: MALIGNANT INFANTILE
OSTEOPETROSIS
Next-generation sequencing identified a pathogenic mutation in the T-cell immune regulator 1 (TCIRG1) gene
(c.1674-1G>A), which confirmed the suspicion of malignant infantile osteopetrosis (MIO). This gene is associated with an autosomal recessive form of MIO. As only one
pathogenic mutation was found, deletion/duplication and
whole-exome sequencing were undertaken to identify a
second mutation, however, no relevant abnormalities were
identified. It is possible a second TCIRG1 mutation is present which current genetic testing technology cannot detect,
as previous reports have described patients with a clinical
phenotype of MIO with only one identified mutation (1).
With the corresponding clinical phenotype, we proceeded
with definitive management for MIO, which is bone marrow
transplantation (BMT). The patient’s brother was a favourable HLA match. In preparation for transplant, a CT head
demonstrated obstructive hydrocephalus with transependymal edema and splaying of the skull fissures. The patient had
a ventriculo-peritoneal shunt inserted with subsequent resolution of hydrocephalus. She underwent a successful allogeneic BMT and is currently in follow-up but unfortunately,
has ongoing visual impairment.
Autosomal recessive MIO is the most severe form of osteopetrosis, with an estimated annual incidence of 1/100,000 to
500,000. It is a disorder of bone remodelling caused by failure
of osteoclasts to resorb immature bone (2). This leads to abnormal bone marrow cavity formation and subsequent displacement of hematopoietic cells from the medullary cavity,
resulting in extramedullary hematopoiesis and possible bone
marrow failure (anemia, infection, and blasts on peripheral

Figure 2. Frayed metaphyses of humeral heads and scapula, expansion of
anterior ribs at costochondral junctions.
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smear). Impaired bone remodelling can cause narrowing of cranial nerve foramina resulting in optic nerve compression, visual
impairment, or obstructed cerebrospinal fluid flow and hydrocephalus. Abnormal remodelling of primary bone to lamellar
bone leads to bones that are prone to fracture. These abnormalities result in the classic features of the disease: bone marrow
failure, visual impairment, and fractures.
Children often present within the first 3 months of life, frequently due to parental concern for the child’s vision. Other
common presentations include failure to thrive and recurrent
infections (3). Less common presentations include hypocalcemic seizures, bruising, fractures, nasal congestion, and abnormal craniofacial appearance. A diagnosis of MIO relies strongly
on clinical suspicion. Visual impairment, hypocalcemia, and
anemia can suggest a diagnosis of MIO. Typical x-ray findings
of sclerotic bony changes, as seen in our patient, can help support the diagnosis with confirmation of sclerosis through bone
biopsy.
When assessing a neonate presenting with hypocalcemia,
such as our patient, it is important to confirm that this is a true
result using ionized calcium. Then, assess the status of other extended electrolytes including magnesium and phosphate, which
if low, could indicate losses through either the GI or renal systems. A 24-hour urine sample could be considered to accurately
assess potential losses. Concurrently, investigate for a potential
endocrinologic cause by obtaining both PTH and 25-hydroxy
vitamin D levels. An elevated PTH indicates a secondary

Figure 3. Enlarged lateral ventricles on magnetic resonance imaging.
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hyperparathyroidism which has numerous causes including
vitamin D-dependent rickets. In this case, vitamin D levels
would be low. A low or inappropriately normal PTH along with
a normal vitamin D level would indicate hypoparathyroidism,
for which a separate workup would need to be initiated (2). If
despite these investigations, a diagnosis is not clear, it is then
worthwhile to consider rarer causes such as osteopetrosis.
Genetic investigation is needed to confirm the diagnosis.
MIO is a heterogeneous disease with numerous possible associated genetic loci. A pathogenic heterozygous mutation in
TCIRG1, as seen in our patient, has been associated with MIO.
TCIRG1 codes for vacuolar H+ ATPase which plays an essential role in osteoclast function. Autosomal dominant forms of
osteopetrosis are more benign.
Management of MIO involves supportive treatment until
curative BMT. Patients with MIO can have severe pancytopenia and may become transfusion dependent. Failure
to thrive is another common complication, which requires
a team of allied health professionals to optimize growth in
preparation for transplantation. Medical therapies including
steroids, calcitriol and interferon gamma-1B have been studied; however, BMT is the only treatment shown to alter the
disease’s course (4).
MIO has a high mortality rate in those with severe disease
and bone marrow failure. A common cause of early death is
overwhelming infection. A favourable prognosis is seen in
patients who are not transfusion dependent and alive at age two
(3). Timing of BMT can affect outcomes significantly, as delay
can cause complications including visual loss and obstructive
hydrocephalus. Although BMT will halt further disease progression, previous morbidity from bone remodelling cannot be
reversed.
Hypophosphatemia is an unusual presenting symptom of MIO.
The development of hypocalcemia in our patient eventually led to
the diagnosis, as this along with her distinctive x-ray findings and
signs of bone marrow failure are classic features of the disease.

CLINICAL PEARLS
1. Bony changes on plain films, including striking sclerosis,
may be the first sign of MIO.
2. The combination of hypocalcemia, cytopenias, and bony abnormalities (on x-ray and clinical exam) may indicate early
MIO.
3. Timely BMT can be life-saving in MIO and significantly decreases morbidity. Therefore, early recognition of this rare
condition is essential and genetic counselling is important
for the family.
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